Synthetic lethality is an emerging therapeutic strategy that exploits a specific vulnerability in cancer cells by targeting a second, non-mutated gene that tumor cells with a mutated tumor suppressor gene are uniquely dependent on for survival. This approach selectively kills the cancer cells while sparing healthy cells, which retain a functional copy of the tumor suppressor gene.

However, identifying these critical genes often requires testing thousands of compounds. This is where High-Throughput Screening (HTS) becomes essential, enabling researchers to evaluate vast libraries of compounds and uncover novel therapeutic targets. While HTS accelerates drug discovery, performing these assays manually poses several challenges, such as human error, low precision at sub-microliter volumes, limited reproducibility, time and labor intensiveness, as well as high costs.